Loading company
Northwest Biotherapeutics Inc.
NWBO · OTC
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
Northwest Biotherapeutics Inc. is not in the industry map, so there is nobody to compare it against yet. The map covers listed US tickers and is refreshed periodically.
Three ratings, each a percentile against the 134 companies it is measured with. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.
Not enough data to rank
The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.
Not enough data to rank
Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. All five measures available.
5 checks not reported
What management does with the money — scored on whatever the filings answer, never as a share of the total.
A description of where this company sits among its competitors, not a recommendation.
NWBO · OTC
Figures through September 30, 2026, from the 10-Q filed November 13, 2026